<DOC>
	<DOCNO>NCT00958386</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety combination Panitumumab Irinotecan patient Wild-Type KRAS metastatic colorectal cancer refractory irinotecan base chemotherapy .</brief_summary>
	<brief_title>Safety Efficacy Study Panitumumab+Irinotecan Patients Wild-Type ( WT ) KRAS Metastatic Colorectal Cancer Refractory Irinotecan Based Chemotherapy ( SPECTRA )</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Competent comprehend , sign , date IECapproved inform consent form . Men woman 18 year age old time write informed consent obtain . Histologically confirm metastatic adenocarcinoma colon rectum WildType KRAS ( No mutation ) allelic discrimination tumor DNA . Karnofsky performance status ≥ 70 % time enrolment study . Within seven day prior initiate study treatment : Adequate bone marrow function : neutrophil ≥ 1.5x109/ L ; platelet ≥ 100x109/L ; hemoglobin ≥ 9g/dL . Hepatic function follow : total bilirubin count ≤ 1.5 x ULN ; ALAT ASAT ≤ 2.5 x ULN ( ≤5 x ULN case liver metastasis ) . Renal function : serum creatinine ≤1.5 ULN Metabolic function : magnesium ≥ low limit normal ( LLN ) , calcium ≥ low limit normal ( LLN ) Life expectancy ≥ 3 month . Prior malignant tumor last 5 year , except history basal cell carcinoma skin preinvasive cervical cancer . Unresolved toxicity prior systemic therapy , opinion investigator , qualify patient inclusion . Documented suspected central nervous system metastasis . Hormonal therapy , immunotherapy experimental approve proteins/antibodies ( eg , Bevacizumab ) ≤ 30 day inclusion . Significant cardiovascular disease include unstable angina myocardial infarction within 12 month initiate study treatment history ventricular arrhythmia . Prior antiEGFr antibody therapy ( eg , Cetuximab ) treatment small molecule EGFr tyrosine kinase inhibitor ( eg , Erlotinib ) EGFR signal transduction inhibitor . Subjects discontinue first dose antiEGFR therapy ( Cetuximab ) infusion reaction may participate clinical trial . Paraffinembedded tissue unstained tumor slide primary metastatic tumor available ( block available Translational research ) . History interstitial pneumonitis pulmonary fibrosis evidence interstitial pneumonitis pulmonary fibrosis baseline chest CT scan . Treatment systemic infection within 14 day initiate study treatment . Acute subacute intestinal occlusion /or active inflammatory bowel disease bowel disease cause chronic diarrhoea ( define &gt; 4 loose stool per day ) . History Gilbert 's syndrome dihydropyrimidine deficiency . History medical condition may increase risk associate study participation may interfere interpretation study result . Known positive test human immunodeficiency virus infection , hepatitis C virus , chronic active hepatitis B infection . Subject allergic ingredient study medication Staphylococcus protein A . Any comorbid disease would increase risk toxicity . Any kind disorder compromise ability subject give write informed consent and/or comply study procedure . Any investigational agent within 30 day initiation treatment . Subject pregnant breast feeding . Surgery ( exclude diagnostic biopsy central venous catheter placement ) and/or radiotherapy within 28 day prior initiation study treatment . Woman man childbearing potential consenting use adequate contraceptive precaution i.e . double barrier contraceptive method ( e.g . diaphragm plus condom ) , abstinence course study 6 month last study drug administration woman , 1 month men . Subject unwilling unable comply study requirement . Psychological , familial , sociological , geographical condition potentially hamper compliance study protocol followup schedule ; condition discuss patient registration trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>Panitumumab</keyword>
	<keyword>irinotecan</keyword>
</DOC>